DK2790687T3 - Trpc4-modulatorer til anvendelse i behandling eller forebyggelse af smerte - Google Patents

Trpc4-modulatorer til anvendelse i behandling eller forebyggelse af smerte Download PDF

Info

Publication number
DK2790687T3
DK2790687T3 DK12806318.7T DK12806318T DK2790687T3 DK 2790687 T3 DK2790687 T3 DK 2790687T3 DK 12806318 T DK12806318 T DK 12806318T DK 2790687 T3 DK2790687 T3 DK 2790687T3
Authority
DK
Denmark
Prior art keywords
pain
pharmaceutical composition
use according
model
trpc4
Prior art date
Application number
DK12806318.7T
Other languages
English (en)
Inventor
John Stuart Crawford
Eric M Ostertag
Original Assignee
Poseida Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poseida Therapeutics Inc filed Critical Poseida Therapeutics Inc
Application granted granted Critical
Publication of DK2790687T3 publication Critical patent/DK2790687T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Claims (11)

1. Farmaceutisk sammensætning, der omfatter 4-methyl-2-piperidin-l-yl-quinolin med formlen
til anvendelse i reduktion eller forebyggelse af smerte hos et pattedyr ved modulering af TRPC4-aktivitet, hvor smerten er valgt fra akut, kronisk, neuropatisk, nociceptiv og visceral smerte eller en kombination deraf.
2. Farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor smerten omfatter visceral smerte.
3. Farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor smerten omfatter neuropatisk smerte.
4. Farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor den farmaceutiske sammensætning administreres oralt, og hvor den virksomme mængde af 4-methyl-2-piperidin-1-yl-quinolin er ekstrapoleret fra assays in vitro og in vivo valgt fra halebevægelsesmodellen (Tail Flick Model), rottehalenedsænkningsmodellen (Rat Tail Immersion Model) og den carageenan-inducerede potehyperalgesimodel (Carageenan-induced Paw Hyperalgesia Model).
5. Farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor den farmaceutiske sammensætning administreres topisk, og hvor den virksomme mængde af 4-methyl-2-piperidin-l-yl-quinolin er ekstrapoleret fra assays in vitro og in vivo valgt fra halebevægelsesmodellen, rottehalenedsænkningsmodellen og den carageenan-inducerede potehyperalgesimodel.
6. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-3, der endvidere omfatter mindst ét supplerende farmaceutisk aktivt middel.
7. Farmaceutisk sammensætning til anvendelse ifølge krav 6, hvor det mindst ene supplerende farmaceutisk aktive middel er valgt fra non-opioide analgetika, opioide analgetika, antiepileptika, NMDA-antagonister, lidocain, tricykliske antidepressiva eller en kombination deraf.
8. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-3, 6 eller 7, hvor den farmaceutiske sammensætning administreres oralt.
9. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-3, 6 eller 7, hvor den farmaceutiske sammensætning administreres topisk.
10. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-3 eller 6-9, hvor den kroniske smerte er smerte forbundet med cancer.
11. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-3 eller 6-9, hvor den akutte smerte er smerte forbundet blødvævslæsion, infektion eller inflammation.
DK12806318.7T 2011-12-16 2012-12-14 Trpc4-modulatorer til anvendelse i behandling eller forebyggelse af smerte DK2790687T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161576619P 2011-12-16 2011-12-16
PCT/US2012/069753 WO2013090722A1 (en) 2011-12-16 2012-12-14 Trpc4 modulators for use in the treatment or prevention of pain

Publications (1)

Publication Number Publication Date
DK2790687T3 true DK2790687T3 (da) 2018-11-19

Family

ID=47430150

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12806318.7T DK2790687T3 (da) 2011-12-16 2012-12-14 Trpc4-modulatorer til anvendelse i behandling eller forebyggelse af smerte

Country Status (17)

Country Link
US (2) US10131634B2 (da)
EP (2) EP3485889B1 (da)
JP (3) JP2015500345A (da)
AU (2) AU2012352083B2 (da)
CA (1) CA2859283C (da)
CY (1) CY1121293T1 (da)
DK (1) DK2790687T3 (da)
ES (1) ES2692546T3 (da)
HR (1) HRP20181746T1 (da)
HU (1) HUE041294T2 (da)
LT (1) LT2790687T (da)
PL (1) PL2790687T3 (da)
PT (1) PT2790687T (da)
RS (1) RS57919B1 (da)
SI (1) SI2790687T1 (da)
TR (1) TR201815535T4 (da)
WO (1) WO2013090722A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2790687T (pt) * 2011-12-16 2018-11-13 Poseida Therapeutics Inc Moduladores de trpc4 para uso no tratamento ou prevenção da dor
KR20210136106A (ko) * 2019-04-11 2021-11-16 데이진 화-마 가부시키가이샤 벤즈이미다졸 유도체 및 이들의 용도

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
HU198036B (en) * 1983-08-22 1989-07-28 Hoechst Roussel Pharma Process for production of derivatives of 3-piperidil-/1h/-indasole and medical preparatives containing them
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
DE69231467T2 (de) 1991-05-10 2001-01-25 Genentech Inc Auswählen von agonisten und antagonisten von liganden
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5656449A (en) * 1995-03-06 1997-08-12 Molecular Probes, Inc. Neutral unsymmetrical cyanine dyes
WO1997000271A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
EP0974111B1 (en) 1997-04-11 2003-01-08 California Institute Of Technology Apparatus and method for automated protein design
US6403312B1 (en) 1998-10-16 2002-06-11 Xencor Protein design automatic for protein libraries
AU4802500A (en) * 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
US7375125B2 (en) 1999-08-04 2008-05-20 Ore Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
WO2001025277A1 (en) 1999-10-07 2001-04-12 Maxygen Aps Single-chain antagonist polypeptides
US20020072101A1 (en) 2000-01-21 2002-06-13 Gaughan Glen T. Novel human nucleic acid molecules and polypeptides encoding cation channels
WO2002044210A2 (en) 2000-12-01 2002-06-06 Bristol-Myers Squibb Company Novel human nucleic acid molecules and polypeptides encoding a novel human ion channel expressed in spinal cord and brain
AU2002316150A1 (en) 2001-05-22 2002-12-03 Bristol-Myers Squibb Company Polynucleotide encoding a novel trp channel family member, trp-plik2, and splice variants thereof
US6740649B2 (en) * 2001-09-17 2004-05-25 Bristol-Myers Squibb Company Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF- α converting enzyme (TACE)
PE20030701A1 (es) * 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
WO2003057843A2 (en) * 2001-12-31 2003-07-17 Algos Therapeutics, Inc. Methods and materials for modulating trpc4
KR20040073565A (ko) * 2002-01-15 2004-08-19 가부시끼가이샤 도시바 냉매누출을 알리는 알림장치를 구비한 냉장고
AU2003280654A1 (en) * 2002-10-31 2004-05-25 Kunihiro Tamura Golf club with which gravity rule is realized
US7256200B2 (en) 2003-02-10 2007-08-14 The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois Method and composition for potentiating an oplate analgesic
KR100561646B1 (ko) * 2003-10-23 2006-03-20 엘지.필립스 엘시디 주식회사 표시 소자용 박막 트랜지스터 기판 및 그 제조 방법
WO2005087742A1 (en) * 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
US20070196866A1 (en) 2004-03-13 2007-08-23 Irm Llc Modulators of ion channel trpa1
DE102004017932A1 (de) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7524862B2 (en) 2004-04-14 2009-04-28 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
WO2007025613A2 (en) * 2005-07-15 2007-03-08 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
WO2008003702A2 (en) 2006-07-03 2008-01-10 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Fused bicyclic compounds interacting with the histamine h4 receptor
GB0615136D0 (en) 2006-07-29 2006-09-06 Univ Edinburgh Induction of analgesia in neuropathic pain
US20090131302A1 (en) 2007-04-11 2009-05-21 Pasricha Pankaj J Transient receptor potential vanilloid 1 and uses thereof
WO2009005602A2 (en) * 2007-06-27 2009-01-08 Dolby Laboratories Licensing Corporation Incremental construction of search tree with signature pointers for identification of multimedia content
CN101868443A (zh) 2007-09-20 2010-10-20 特拉维夫大学拉莫特有限公司 N-苯基邻氨基苯甲酸衍生物及其用途
US8084616B2 (en) 2007-10-24 2011-12-27 Abbott Laboratories TRPV1 antagonists
US7998993B2 (en) 2007-10-25 2011-08-16 Abbott Laboratories TRPV1 antagonists
KR20090047637A (ko) 2007-11-08 2009-05-13 재단법인서울대학교산학협력재단 커큐민 또는 이의 약학적으로 허용가능한 염을유효성분으로 함유하는 통증 예방 및 치료용 조성물
CA2706566A1 (en) 2007-12-18 2009-07-09 Glenmark Pharmaceuticals, S.A. Chromane derivatives as trpv3 modulators
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP4545828B2 (ja) * 2008-12-19 2010-09-15 パナソニック株式会社 画像検索装置及び画像検索方法
EP2467398B1 (en) 2009-08-20 2019-10-09 Poseida Therapeutics, Inc. Trpc4 inhibitors and uses thereof
WO2011022634A2 (en) * 2009-08-20 2011-02-24 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for pain
DE102009046649A1 (de) 2009-11-12 2011-05-19 Robert Bosch Gmbh Klimakompressor für ein Fahrzeug, Fahrzeug
CA2798325A1 (en) * 2010-05-13 2011-11-17 Amgen Inc. Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
PT2790687T (pt) * 2011-12-16 2018-11-13 Poseida Therapeutics Inc Moduladores de trpc4 para uso no tratamento ou prevenção da dor

Also Published As

Publication number Publication date
US20190135759A1 (en) 2019-05-09
RS57919B1 (sr) 2019-01-31
JP2018030875A (ja) 2018-03-01
EP2790687A1 (en) 2014-10-22
AU2012352083A1 (en) 2014-07-17
LT2790687T (lt) 2018-12-10
AU2018202172A1 (en) 2018-04-26
CY1121293T1 (el) 2020-05-29
AU2018202172B2 (en) 2019-12-19
WO2013090722A1 (en) 2013-06-20
EP3485889B1 (en) 2023-09-06
JP6534716B2 (ja) 2019-06-26
SI2790687T1 (sl) 2019-01-31
HUE041294T2 (hu) 2019-05-28
ES2692546T3 (es) 2018-12-04
EP2790687B1 (en) 2018-08-29
US10131634B2 (en) 2018-11-20
TR201815535T4 (tr) 2018-11-21
JP2019135271A (ja) 2019-08-15
PL2790687T3 (pl) 2019-03-29
HRP20181746T1 (hr) 2018-12-28
CA2859283C (en) 2021-03-09
CA2859283A1 (en) 2013-06-20
AU2012352083B2 (en) 2018-01-04
JP6858808B2 (ja) 2021-04-14
JP2015500345A (ja) 2015-01-05
US20140329856A1 (en) 2014-11-06
PT2790687T (pt) 2018-11-13
EP3485889A1 (en) 2019-05-22

Similar Documents

Publication Publication Date Title
RU2566821C2 (ru) Модулятор nmda-рецептора со стабилизированной вторичной структурой и его применение
JP2021185146A (ja) アルギナーゼ活性を阻害するための組成物および方法
De Vry et al. Neuroprotective and behavioral effects of the selective metabotropic glutamate mGlu1 receptor antagonist BAY 36-7620
Husain et al. Opioid receptor-activation: retina protected from ischemic injury
JP2014532669A (ja) Ｎ−ベンジルアニリン誘導体及びその使用
AU2018202172B2 (en) TRPC4 modulators for use in the treatment or prevention of pain
KR20080035658A (ko) 신경병증 및 관련 장애를 치료하기 위한 방법 및 조성물
WO2021066144A1 (ja) ヘテロシクリデンアセトアミド誘導体含有医薬
KR20120099212A (ko) 트라마돌 및 콕시브의 공결정
TW201336500A (zh) 治療疼痛之方法及組合物
RU2707191C2 (ru) Нейродегенеративные расстройства
EP2945627A1 (en) Use of selective delta-opioid receptor antagonists and specific sensory receptor ligands
CZ299423B6 (cs) Nové BPC peptidové sole s organo-protektivní aktivitou, proces jejich prípravy a jejich použití v lécbe
CA2458388A1 (en) Novel benzothiazine derivatives, their preparation and use
US20160000804A1 (en) Inhibitors of na(v) 1.9 channel activity and uses thereof for treating pain
TW201900603A (zh) Trpv1調節劑化合物
JP2023527942A (ja) 粒子状グアニリルシクラーゼ受容体ａのエンハンサー
CN105943534A (zh) 用于局部治疗免疫相关疾病的局部lfa-1拮抗剂
Frajmund Functional Effects of the Relaxin-3/RXFP-3 Pathway on the Affective Dimension of Chronic Pain
Alamri Relationship between Structure, Molecular phenotype and Function of Corneal Sensory Neurons and their Nerve Terminal Endings
Fialová Acute and chronic effects of sigma receptor ligands in mammalian myocardium
AU2002333216A1 (en) Novel benzothiazine derivatives, their preparation and use